AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20956120 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost in combination with oral bosentan
Number of subjects: 0
Study 16846448 — intervention group
Group type: EXPERIMENTAL
Intervention: Ding Chuan Tang (DCT) 6.0 g daily for 12 weeks
Number of subjects: 52
Study 16846448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12968988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg orally once daily for 5 days
Number of subjects: 10
Study 12968988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10895398 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 9324168 — intervention group
Group type: EXPERIMENTAL
Intervention: UDP-galactosyltransferase activity in gastric mucosa of cirrhotic patients
Number of subjects: 0
Study 9324168 — intervention group
Group type: COMPARATOR
Intervention: UDP-galactosyltransferase activity in gastric mucosa of patients with chronic hepatitis
Number of subjects: 0
Study 9324168 — intervention group
Group type: COMPARATOR
Intervention: UDP-galactosyltransferase activity in gastric mucosa of normal controls
Number of subjects: 0
Study 8375733 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon-beta (IFN-beta) at two different dose levels (2 x 10(6) IU or 6 x 10(6) IU im 3 times/week for 1 week)
Number of subjects: 43
Study 3791630 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antigen avoidance (dietary advice consisting of almost complete exclusion of milk and dairy products, egg, fish, beef, and peanut throughout pregnancy and lactation)
Number of subjects: 121
Study 3791630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary restriction)
Number of subjects: 121
Study 29614063 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (FFO group)
Number of subjects: 0
Study 29614063 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (FFIO group)
Number of subjects: 0
Study 29614063 — intervention group
Group type: COMPARATOR
Intervention: Surgery (Control group)
Number of subjects: 0
Study 26922655 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication discontinuation
Number of subjects: 325
Study 26922655 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful discontinuation (defined as no relapse within the observation period)
Number of subjects: 325
Study 26922655 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful discontinuation (defined as no relapse and symptomatic remission at 12-month follow-up)
Number of subjects: 325
Study 26922655 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation predictors
Number of subjects: 325
Study 26922655 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and compliance
Number of subjects: 325
Study 26922655 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful discontinuation predictors (definition a)
Number of subjects: 325
Study 26922655 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful discontinuation predictors (definition b)
Number of subjects: 325
Study 23718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Saucer-shaped defects
Number of subjects: 83
Study 23718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge-shaped defects
Number of subjects: 83
Study 23718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat defects
Number of subjects: 83
Study 23718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Undercut defects
Number of subjects: 83
Study 23718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-like defects
Number of subjects: 83
Study 23718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer reliability
Number of subjects: 83
Study 23718182 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of PIBD type
Number of subjects: 83
Study 22813676 — intervention group
Group type: EXPERIMENTAL
Intervention: WPS (Workplace Solutions) intervention group
Number of subjects: 48
Study 22813676 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 22813676 — intervention group
Group type: EXPERIMENTAL
Intervention: Total best-practice implementation
Number of subjects: 48
Study 20506282 — intervention group
Group type: EXPERIMENTAL
Intervention: EPC stent
Number of subjects: 100
Study 20506282 — intervention group
Group type: COMPARATOR
Intervention: CoCr stent
Number of subjects: 100
Study 18942901 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg tid; n = 12)
Number of subjects: 24
Study 18942901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study 16158479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (n=74)
Number of subjects: 139
Study 16158479 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=65)
Number of subjects: 139
Study 12934778 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (Oxytrol, 3.9 mg/d)
Number of subjects: 13
Study 12934778 — intervention group
Group type: COMPARATOR
Intervention: Extended-release oral oxybutynin (Ditropan XL, 10 mg)
Number of subjects: 13
Study 10393376 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (trimethoprim, 320 mg/day; sulfamethoxazole, 1,600 mg/day)
Number of subjects: 97
Study 10393376 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics (control group)
Number of subjects: 97
Study 8894571 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT) 1 g/day
Number of subjects: 36
Study 8894571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8236992 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 30
Study 8236992 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 30
Study 3318145 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg PG E2 endocervically
Number of subjects: 158
Study 3318145 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PG E2 intravaginally
Number of subjects: 158
Study 3318145 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous onset of labour (control group)
Number of subjects: 158
Study 3318145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapeutic oxytocin sensitivity test
Number of subjects: 158
Study 29798906 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1775
Number of subjects: 20
Study 25967528 — intervention group
Group type: EXPERIMENTAL
Intervention: AGV with MMC (group B)
Number of subjects: 75
Study 25967528 — intervention group
Group type: EXPERIMENTAL
Intervention: AGV with AMT (group C)
Number of subjects: 75
Study 25967528 — intervention group
Group type: COMPARATOR
Intervention: Conventional AGV implantation (group A)
Number of subjects: 75
Study 26455718 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 240
Study 26455718 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial endometrial cycle treatment (AEC)
Number of subjects: 240
Study 26455718 — intervention group
Group type: COMPARATOR
Intervention: Comforting false Han's placebo (FHP)
Number of subjects: 240
Study 26455718 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 240
Study 24385637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrivers
Number of subjects: 2793
Study 24385637 — intervention group
Group type: COMPARATOR
Intervention: Drivers
Number of subjects: 2793
Study 24385637 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-city residents
Number of subjects: 2793
Study 24385637 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-city residents
Number of subjects: 2793
Study 20807919 — intervention group
Group type: EXPERIMENTAL
Intervention: Left arm in an above-the-elbow thumb spica splint
Number of subjects: 36
Study 20807919 — intervention group
Group type: EXPERIMENTAL
Intervention: Left arm in a below-the-elbow splint
Number of subjects: 36
Study 20807919 — intervention group
Group type: EXPERIMENTAL
Intervention: All splints
Number of subjects: 36
Study 17977859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.165% with sufentanil 1 microg ml(‐1)
Number of subjects: 100
Study 17977859 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.125% with sufentanil 1 microg ml(‐1)
Number of subjects: 100
Study 17977859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.165%
Number of subjects: 100
Study 17977859 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 0.125%
Number of subjects: 100
Study 16365120 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamping the drains after intra‐articular injection of saline with 1:500 000 adrenaline
Number of subjects: 212
Study 16365120 — intervention group
Group type: COMPARATOR
Intervention: Post-operative blood salvage
Number of subjects: 212
Study 14710587 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief exposure of gametes
Number of subjects: 0
Study 14710587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 0
Study 14710587 — intervention group
Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF)
Number of subjects: 0
Study 10847459 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil-5-FU
Number of subjects: 75
Study 10847459 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil-5-FU-LV
Number of subjects: 75
Study 10847459 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniluracil-5-FU (refractory stratum)
Number of subjects: 75
Study 7674690 — intervention group
Group type: EXPERIMENTAL
Intervention: Judicious prescription of therapies in stepwise fashion
Number of subjects: 0
Study 2469338 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline‐dextran solution
Number of subjects: 48
Study 2469338 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid plasmalyte A
Number of subjects: 48
Study 407377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose diet
Number of subjects: 16
Study 407377 — intervention group
Group type: COMPARATOR
Intervention: Non-lactose diet
Number of subjects: 16
Study 30737094 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based online training
Number of subjects: 131
Study 30737094 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention comparison group
Number of subjects: 131
Study 28004376 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilmapimod
Number of subjects: 0
Study 28004376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28247686 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone level
Number of subjects: 131
Study 28247686 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak systolic velocity of blood flow in the capsular arteries of testes
Number of subjects: 131
Study 28247686 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular size
Number of subjects: 131
Study 28247686 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum testosterone levels
Number of subjects: 131
Study 23328847 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-frequency nerve ablation (RFNA)
Number of subjects: 17
Study 23328847 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 17
Study 23328847 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-frequency nerve ablation (RFNA) after crossover from sham treatment
Number of subjects: 17
Study 21299254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 52
Study 21299254 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 52
Study 19287286 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 52
Study 19287286 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bevacizumab
Number of subjects: 52
Study 19287286 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 52
Study 16754351 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy with hyperthermia
Number of subjects: 137
Study 16754351 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant radiochemotherapy without hyperthermia
Number of subjects: 137
Study 14969649 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/metformin plus rosiglitazone (4 mg once daily)
Number of subjects: 365
Study 14969649 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide/metformin plus rosiglitazone
Number of subjects: 365
Study 14969649 — intervention group
Group type: COMPARATOR
Intervention: Glyburide/metformin plus placebo
Number of subjects: 365
Study 14969649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone-treated group
Number of subjects: 365
Study 11515892 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 69
Study 11515892 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon Aminocaproic Acid (EACA)
Number of subjects: 69
Study 11515892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9403284 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1 g b.i.d. for 5 days
Number of subjects: 10
Study 9403284 — intervention group
Group type: COMPARATOR
Intervention: Dirithromycin 500 mg qd for 5 days
Number of subjects: 10
Study 8144986 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (4 Gy per fraction, three fractions per week to a total dose of 24 Gy)
Number of subjects: 49
Study 8144986 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with hyperthermia (same radiotherapy regimen, regional hyperthermia for 35‐60 min after irradiation, two sessions per week to a total of four sessions)
Number of subjects: 49
Study 8144986 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (low)
Number of subjects: 49
Study 2975806 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 73
Study 2975806 — intervention group
Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 73
Study 2975806 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine
Number of subjects: 73
Study 2975806 — intervention group
Group type: COMPARATOR
Intervention: zimelidine
Number of subjects: 73
Study 31084381 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (400 mg daily for 12 weeks)
Number of subjects: 20
Study 28193771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 0
Study 28193771 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 24180479 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. mitoxantrone (MTX), oral vinorelbine, or oral etoposide, together with oral prednisone
Number of subjects: 92
Study 24180479 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 92
Study 23242572 — intervention group
Group type: EXPERIMENTAL
Intervention: NR-INF-02 (500 mg twice daily)
Number of subjects: 120
Study 23242572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mg twice daily)
Number of subjects: 120
Study 23242572 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (GS) (750 mg twice daily)
Number of subjects: 120
Study 23242572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of NR-INF-02 and GS
Number of subjects: 120
Study 21527870 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training + audiovisual training (AV)
Number of subjects: 51
Study 21527870 — intervention group
Group type: COMPARATOR
Intervention: AV only (Control)
Number of subjects: 51
Study 21527870 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training + AV
Number of subjects: 51
Study 18083691 — intervention group
Group type: EXPERIMENTAL
Intervention: ILF (irinotecan 150 mg/m², leucovorin 20 mg/m², 5-FU 1000 mg/m² on days 1 and 2)
Number of subjects: 91
Study 18083691 — intervention group
Group type: COMPARATOR
Intervention: PILF (ILF plus cisplatin 30 mg/m² on day 2)
Number of subjects: 91
Study 18083691 — intervention group
Group type: EXPERIMENTAL
Intervention: ILF
Number of subjects: 91
Study 18083691 — intervention group
Group type: COMPARATOR
Intervention: PILF
Number of subjects: 91
Study 16939360 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 17
Study 16939360 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 17
Study 16939360 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 17
Study 12660333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12660333 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg once daily)
Number of subjects: 20
Study 12660333 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once daily)
Number of subjects: 20
Study 12660333 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade (20 mg benazepril + 80 mg valsartan)
Number of subjects: 20
Study 10971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevioside (250 mg) thrice daily
Number of subjects: 106
Study 10971305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 8832991 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg equivalent)
Number of subjects: 99
Study 8832991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxipurinol sodium
Number of subjects: 99
Study 8832991 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 99
Study 1449107 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 540 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Number of subjects: 15
Study 1449107 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 450 mg/m2 with folinic acid (FA) 500 mg/m2 and rhGM-CSF
Number of subjects: 15
Study 6150276 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg or 150 mg kanamycin plus gentamicin eye ointment (for 3 days)
Number of subjects: 117
Study 6150276 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose kanamycin with saline eye washes (for 3 days)
Number of subjects: 117
Study 6150276 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg kanamycin plus chloramphenicol eye drops
Number of subjects: 117
Study 6150276 — intervention group
Group type: EXPERIMENTAL
Intervention: Postgonococcal conjunctivitis
Number of subjects: 117
Study 6150276 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal infection with N gonorrhoeae
Number of subjects: 117
Study 30371557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 0
Study 30371557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30371557 — intervention group
Group type: COMPARATOR
Intervention: BISAD, Checklist of Nonverbal Pain Indicators, Algoplus
Number of subjects: 0
Study 28443675 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar proximal injection approach
Number of subjects: 38
Study 28443675 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar distal injection approach
Number of subjects: 38
Study 28443675 — intervention group
Group type: EXPERIMENTAL
Intervention: Webspace injection approach
Number of subjects: 38
Study 26676838 — intervention group
Group type: EXPERIMENTAL
Intervention: O2-O3 intradiscal injection
Number of subjects: 517
Study 24832476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Mind Fitness Training (MMFT)
Number of subjects: 281
Study 24832476 — intervention group
Group type: COMPARATOR
Intervention: Training-as-usual control condition
Number of subjects: 281
Study 21884857 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin Heart EXCOR Pediatric ventricular assist device (VAD)
Number of subjects: 48
Study 21884857 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal membrane oxygenation (control)
Number of subjects: 48
Study 19012050 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated estrogen (CE) + 2.5 mg medroxyprogesterone acetate (MPA)/day
Number of subjects: 95
Study 19012050 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone/day
Number of subjects: 95
Study 19012050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 95
Study 16918861 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive school-based asthma program facilitated by trained school nurses and PCP training.
Number of subjects: 0
Study 16918861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 0
Study 14725828 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse home visit
Number of subjects: 174
Study 14725828 — intervention group
Group type: COMPARATOR
Intervention: Consultant clinic review
Number of subjects: 174
Study 11505044 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0, 50, 125, 375, and 500 microg/kg)
Number of subjects: 64
Study 11505044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9023459 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (7 g)
Number of subjects: 0
Study 9023459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (17 g)
Number of subjects: 0
Study 9023459 — intervention group
Group type: COMPARATOR
Intervention: Control diet (7 g of sucrose)
Number of subjects: 0
Study 8420063 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 plus azathioprine and steroids for 14 days with delayed addition of cyclosporine on day 11
Number of subjects: 215
Study 8420063 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression (steroids, azathioprine, and cyclosporine)
Number of subjects: 215
Study 3106632 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg/day D‐penicillamine
Number of subjects: 174
Study 3106632 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg D‐penicillamine
Number of subjects: 174
Study 3106632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (D‐penicillamine trial)
Number of subjects: 174
Study 3106632 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 174
Study 3106632 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 174
Study 3106632 — intervention group
Group type: COMPARATOR
Intervention: Placebo (GSTM/AF trial)
Number of subjects: 174
Study 788855 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded compression using specially designed elastic stockings
Number of subjects: 98